Gland Pharma Share Price Jumps 12 Percent, Top Midcap Gainer on 11 August 2026 as Jefferies Upgrades to Buy After Strong Q1 Results

The Gland Pharma share price surged 12 percent on 11 August 2026 to become the top midcap gainer on Indian exchanges. The Gland Pharma share price rally was triggered by strong Q1 FY27 results and a bullish analyst note from Jefferies, which upgraded the stock to Buy citing multiple positive developments including strong US business growth, new CDMO contract wins, and the easing of losses at Cenexi, the company's French pharmaceutical CDMO subsidiary. The Gland Pharma share price jump of 12 percent in a single session reflects the scale of positive surprise in the Q1 results and the significant re-rating Jefferies expects from current levels.

The Gland Pharma share price has been under pressure in recent quarters due to losses from Cenexi, which Gland Pharma acquired to expand its European CDMO presence. Jefferies noted that these losses are beginning to ease, which is a significant positive for the Gland Pharma share price outlook. The Gland Pharma share price move on 11 August 2026 reflects the market's assessment that the worst of the Cenexi-related drag may be over, and that the core business momentum is robust enough to support a higher valuation for the Gland Pharma share price.

Click Here – Get Free Investment Predictions

Gland Pharma Share Price: Why Jefferies Upgraded to Buy

Jefferies sees further upside in the Gland Pharma share price from multiple angles. The first driver is the strong US injectable business, which is the largest revenue contributor for Gland Pharma. The Gland Pharma share price benefits when US formulations revenue grows because the US market offers the highest margins for Indian pharma exporters. The second driver is new CDMO contract wins, where Gland Pharma is increasingly competing for complex biologic and specialty formulation manufacturing contracts that carry higher margins and longer contract durations, both of which are positive for the Gland Pharma share price over the medium term.

The third key driver for the Gland Pharma share price highlighted by Jefferies is the easing trajectory of Cenexi's losses. Cenexi had been generating operating losses since its acquisition, weighing on consolidated group financials and dampening sentiment around the Gland Pharma share price. As Cenexi's performance stabilises and losses narrow, the drag on the Gland Pharma share price from this subsidiary should reduce, improving the consolidated earnings trajectory that supports the Gland Pharma share price valuation. The fourth driver is Gland Pharma's expansion into complex pharmaceutical products such as peptides, oncology injectables, and ophthalmic formulations, which command premium pricing and support the long-term Gland Pharma share price outlook.

Driver	Impact on Gland Pharma Share Price
Strong US injectable growth	Primary revenue driver; higher US volumes expand margins
New CDMO contract wins	Adds revenue visibility and long-term earnings growth
Cenexi losses easing	Reduces consolidated drag; improves group profitability
Complex products expansion	Premium pricing supports medium to long-term valuation

Gland Pharma Share Price: Q1 FY27 Performance in Context

The Gland Pharma share price reaction to Q1 FY27 results underlines the importance of this quarterly period for the company. Q1 FY27 covers the April to June 2026 quarter, a period during which Gland Pharma's US business showed strong volume growth. The Gland Pharma share price had underperformed the pharma index in recent months partly due to Cenexi-related concerns, making the positive Q1 FY27 results a significant re-rating catalyst. Analysts tracking the Gland Pharma share price will now review full-year FY27 earnings estimates upward if the Q1 momentum is sustained.

Gland Pharma is one of India's largest injectable pharma exporters by volume and has a diversified presence across the US, Europe, and rest-of-world markets. The Gland Pharma share price is listed on both NSE and BSE and is a constituent of the Nifty Midcap index. The 12 percent single-day Gland Pharma share price move makes it one of the standout performers in the pharma sector on 11 August 2026 and will attract fresh analyst coverage and institutional investor interest in the stock.

Track the Gland Pharma Share Price and Pharma Sector Research on Univest Screener

What Investors Should Watch for the Gland Pharma Share Price

Investors tracking the Gland Pharma share price should monitor the company's US product filing pipeline, Cenexi quarterly performance updates, and any new CDMO contract announcements that serve as forward indicators for revenue growth. The Gland Pharma share price at current elevated levels, following the 12 percent single-session surge, may see some consolidation as short-term traders book profits. Long-term investors should assess the Gland Pharma share price relative to full-year FY27 and FY28 earnings estimates and the target price set by Jefferies to determine if there is still meaningful upside.

Download the Univest iOS App or Univest Android App to monitor the Gland Pharma share price live and get pharma sector research from Univest.

Conclusion

The Gland Pharma share price jumped 12 percent on 11 August 2026 to become the top midcap gainer after strong Q1 FY27 results and Jefferies upgrading the stock to Buy. Key drivers cited include strong US growth, new CDMO contract wins, expansion into complex products, and the easing of losses at Cenexi. The Gland Pharma share price re-rating reflects improved confidence in the company's earnings trajectory. Investors should review the full Jefferies research note and consult a SEBI-registered advisor before making investment decisions based on the current Gland Pharma share price.

Frequently Asked Questions

What is the Gland Pharma stock today on 11 August 2026?

Ans. The The pharma stock jumped 12 percent on 11 August 2026, making it the top midcap gainer. The Gland Pharma shares rally was driven by strong Q1 FY27 results and Jefferies upgrading the stock to Buy with a higher target price. Investors should check the live The stock price on NSE or BSE for real-time data.

Why did Jefferies upgrade the Gland Pharma stock to Buy?

Ans. Jefferies upgraded the The pharma stock to Buy citing strong US business growth, new CDMO contracts, and the company's ongoing expansion into complex pharmaceutical products. Jefferies also noted that key challenges including losses at Cenexi, the company's French CDMO subsidiary, appear to be easing, improving the Gland Pharma shares growth outlook.

What is CDMO and how does it affect the The stock price?

Ans. CDMO stands for Contract Development and Manufacturing Organization. Gland Pharma is one of India's leading CDMO businesses, manufacturing injectable pharmaceuticals and complex dosage forms for global pharma companies. New CDMO contracts add revenue visibility and growth, which positively impacts the Gland Pharma stock over the medium to long term.

What is Cenexi and how does it affect the The pharma stock?

Ans. Cenexi is a French pharmaceutical CDMO acquired by Gland Pharma. Cenexi's losses had been a drag on the Gland Pharma shares performance in recent quarters. Jefferies noted that Cenexi's losses appear to be easing, which is a positive development for the The stock price outlook as the financial burden from this acquisition reduces over time.

What is the Jefferies target price for Gland Pharma stock?

Ans. Jefferies upgraded the The pharma stock to Buy on 11 August 2026. For the specific target price set by Jefferies, investors should check the latest brokerage research notes directly or on official financial platforms. The target price reflects Jefferies' estimate of the Gland Pharma shares fair value based on the company's earnings growth trajectory.

How does Gland Pharma's US business drive the The stock price?

Ans. The United States is the largest and most profitable market for Gland Pharma. The US business generates the majority of the company's revenues and margins, meaning strong US growth directly boosts the earnings that support the Gland Pharma stock. Growth in injectable volumes and new complex product launches in the US are key drivers of the The pharma stock upside.

Is Gland Pharma shares a buy at current levels?

Ans. Jefferies has upgraded the The stock price to Buy citing strong Q1 FY27 results, US growth, CDMO wins, and easing Cenexi losses. However, investors should review the full research note, assess valuation, and consult a SEBI-registered financial advisor before making an investment decision based on the current Gland Pharma stock.